Showing results (1-10 of 71) with videos related to
Sort By:
Pageof 8
Anticancer Research|July 11, 2006
Dermatological toxicity of ixabepiloneAlison K Conlin, Linda VahdatNature Clinical Practice. Oncology|September 3, 2008
Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?Linda VahdatThe Oncologist|April 2, 2008
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanismsLinda VahdatMolecular Diagnosis & Therapy|December 15, 2007
Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancerAlison K Conlin, Andrew D SeidmanJournal of the National Comprehensive Cancer Network : JNCCN|October 12, 2007
Point: combination versus single-agent chemotherapy: the argument for sequential single agentsAlison K Conlin, Andrew D SeidmanClinical Breast Cancer|July 25, 2008
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunitiesAlison K Conlin, Andrew D SeidmanCurrent Oncology Reports|December 14, 2006
Taxanes in breast cancer: an updateAlison K Conlin, Andrew D SeidmanClinical Breast Cancer|January 23, 2009
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice settingTessa Cigler, Linda VahdatMetal Ions in Life Sciences|March 12, 2019
Copper Depletion as a Therapeutic Strategy in CancerJay Lopez, Divya Ramchandani, Linda VahdatBreast Cancer Research and Treatment|May 16, 2019
Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysisJohn Silberholz, Dimitris Bertsimas, Linda VahdatPageof 8